Alembic Pharmaceuticals Ltd on Friday said it has received approval from the US health regulator for its generic version of Carbidopa, Levodopa and Entacapone tablets used in treatment of Parkinson's disease. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Carbidopa, Levodopa and Entacapone tablets of strengths 12.5 mg/50 mg/200 mg; 18.75 mg/75 mg/200 mg; 25 mg/100 mg/200 mg; 31.25 mg/125 mg/200 mg; 37.5 mg/150 mg/200 mg; and 50 mg/200 mg/200 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo tablets of similar strengths of Orion Corporation, it added. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease, the company said.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Business Standard | 06 Feb 2026 1 more

Alembic Pharmaceuticals Ltd.

06 Feb 2026

769.90

-2.53%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets

pdf

Alembic Pharmaceuticals Ltd.

05 Feb 2026

769.90

-2.53%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Please find attached the intimation of appointment of Mr. Raj Kumar Baheti (DIN:00332079) as Non-Executive Non Independent Director of the Company.

pdf

Alembic Pharmaceuticals Ltd.

05 Feb 2026

769.90

-2.53%

Investor Presentation

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Please find attached herewith the Revised Investor Presentation

pdf

Alembic Pharmaceuticals Ltd.

05 Feb 2026

769.90

-2.53%

to see Rapid results content

Alembic Pharmaceuticals Ltd.

05 Feb 2026

769.90

-2.53%

Result

Alembic Pharmaceuticals Ltd - 533573 - Unaudited Financial Results For Quarter And Nine Months Ended 31St …

BSE India

Unaudited financial results for the quarter and nine months ended 31st December, 2025

pdf

	Dec 2025	Sep 2025	Dec 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	1891.81	1917.06	1702.24	-1.3%	11.1%
Operating Profit Qtr	293.49	315.69	260.22	-7.0%	12.8%
Net Profit Qtr	132.97	184.71	138.42	-28.0%	-3.9%
Earning Per Share Adjusted latest Qtr	6.76	9.40	7.04	-28.1%	-4.0%